
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3335839/publications.pdf Version: 2024-02-01



ADAM LAFEF

#	Article	IF	CITATIONS
1	Pleural Effusion, Necrotizing Pneumonia and Long-Term Morbidity of Respiratory Infection in Childhood. , 2022, , 132-145.		1
2	Transplacental transfer of RSV antibody in Australian First Nations infants. Journal of Medical Virology, 2022, 94, 782-786.	5.0	3
3	Molecular dynamics and functional characterization of I37R-CFTR lasso mutation provide insights into channel gating activity. IScience, 2022, 25, 103710.	4.1	6
4	Genomic testing for children with interstitial and diffuse lung disease (chILD): parent satisfaction, understanding and health-related quality of life. BMJ Open Respiratory Research, 2022, 9, e001139.	3.0	2
5	The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine,the, 2022, 10, 776-784.	10.7	14
6	Prevention and management of respiratory disease in young people with cerebral palsy: consensus statement. Developmental Medicine and Child Neurology, 2021, 63, 172-182.	2.1	33
7	Avatar acceptability: views from the Australian Cystic Fibrosis community on the use of personalised organoid technology to guide treatment decisions. ERJ Open Research, 2021, 7, 00448-2020.	2.6	7
8	Epidemiology of COVID-19 infection in young children under five years: A systematic review and meta-analysis. Vaccine, 2021, 39, 667-677.	3.8	144
9	Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia. Thorax, 2021, 76, 487-493.	5.6	13
10	Community-based interventions for childhood asthma using comprehensive approaches: a systematic review and meta-analysis. Allergy, Asthma and Clinical Immunology, 2021, 17, 19.	2.0	24
11	Cystic fibrosis-related diabetes and lung disease: an update. European Respiratory Review, 2021, 30, 200293.	7.1	27
12	Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies. Frontiers in Pharmacology, 2021, 12, 639475.	3.5	20
13	Significant functional differences in differentiated Conditionally Reprogrammed (CRC)- and Feeder-free Dual SMAD inhibited-expanded human nasal epithelial cells. Journal of Cystic Fibrosis, 2021, 20, 364-371.	0.7	25
14	Antibiotic use for acute respiratory infections among under-5 children in Bangladesh: a population-based survey. BMJ Global Health, 2021, 6, e004010.	4.7	12
15	Rare diseases research and policy in Australia: On the journey to equitable care. Journal of Paediatrics and Child Health, 2021, 57, 778-781.	0.8	10
16	Surfactant protein disorders in childhood interstitial lung disease. European Journal of Pediatrics, 2021, 180, 2711-2721.	2.7	15
17	Assessment of Variation in Care Following Hospital Discharge for Children with Acute Asthma. Journal of Asthma and Allergy, 2021, Volume 14, 797-808.	3.4	4
18	Mind the Gap: Yet More Evidence for the Importance of Education for Children With Uncontrolled Asthma. American Journal of Public Health, 2021, 111, 1183-1185.	2.7	1

#	Article	IF	CITATIONS
19	Detecting pertussis in the pediatric population using respiratory sound events and CNN. Biomedical Signal Processing and Control, 2021, 68, 102722.	5.7	11
20	Child and caregiver experiences and perceptions of asthma self-management. Npj Primary Care Respiratory Medicine, 2021, 31, 42.	2.6	11
21	Collection, Expansion, and Differentiation of Primary Human Nasal Epithelial Cell Models for Quantification of Cilia Beat Frequency. Journal of Visualized Experiments, 2021, , .	0.3	5
22	TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respiratory Research, 2021, 8, e001127.	3.0	13
23	Assessing appropriateness of paediatric asthma management: A populationâ€based sample survey. Respirology, 2020, 25, 71-79.	2.3	8
24	Role of technology in improving knowledge and confidence in asthma management in school staff. Journal of Asthma, 2020, 57, 452-457.	1.7	2
25	Development and validation of a risk score to identify children at risk of life-threatening asthma. Journal of Asthma, 2020, , 1-10.	1.7	2
26	Characterising the types of paediatric adverse events detected by the global trigger tool – CareTrack Kids. Journal of Patient Safety and Risk Management, 2020, 25, 239-249.	0.6	3
27	Nasopharyngeal density of respiratory viruses in childhood pneumonia in a highly vaccinated setting: findings from a case–control study. BMJ Open Respiratory Research, 2020, 7, e000593.	3.0	2
28	A systematic cochrane review of probiotics for people with cystic fibrosis. Paediatric Respiratory Reviews, 2020, 39, 61-64.	1.8	3
29	A phospholipid-based formulation for the treatment of airway inflammation in chronic respiratory diseases. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, 47-58.	4.3	15
30	Dispensing Practices of Fixed Dose Combination Controller Therapy for Asthma in Australian Children and Adolescents. International Journal of Environmental Research and Public Health, 2020, 17, 5645.	2.6	1
31	Novel Antioxidant Therapy with the Immediate Precursor to Glutathione, Î ³ -Glutamylcysteine (GGC), Ameliorates LPS-Induced Cellular Stress in In Vitro 3D-Differentiated Airway Model from Primary Cystic Fibrosis Human Bronchial Cells. Antioxidants, 2020, 9, 1204.	5.1	11
32	Probiotics for people with cystic fibrosis. The Cochrane Library, 2020, 1, CD012949.	2.8	21
33	Assessing the appropriateness of paediatric antibiotic overuse in Australian children: a population-based sample survey. BMC Pediatrics, 2020, 20, 185.	1.7	5
34	Evaluating the Alimentary and Respiratory Tracts in Health and disease (EARTH) research programme: a protocol for prospective, longitudinal, controlled, observational studies in children with chronic disease at an Australian tertiary paediatric hospital. BMJ Open, 2020, 10, e033916.	1.9	4
35	The intestinal virome in children with cystic fibrosis differs from healthy controls. PLoS ONE, 2020, 15, e0233557.	2.5	11
36	Distress during airway sampling in children with cystic fibrosis. Archives of Disease in Childhood, 2019, 104, 806-808.	1.9	4

#	Article	IF	CITATIONS
37	Air and Fluid in the Pleural Space. , 2019, , 1007-1026.e3.		2
38	Longâ€ŧerm morbidity of respiratory viral infections during chemotherapy in children with leukaemia. Pediatric Pulmonology, 2019, 54, 1821-1829.	2.0	7
39	Targeted Activation of Cystic Fibrosis Transmembrane Conductance Regulator. Molecular Therapy, 2019, 27, 1737-1748.	8.2	25
40	Children's interstitial and diffuse lung disease. The Lancet Child and Adolescent Health, 2019, 3, 568-577.	5.6	33
41	Assessing the adherence to guidelines in the management of croup in Australian children: a population-based sample survey. International Journal for Quality in Health Care, 2019, 31, 759-767.	1.8	2
42	Impact of influenza on hospitalization rates in children with a range of chronic lung diseases. Influenza and Other Respiratory Viruses, 2019, 13, 233-239.	3.4	24
43	Quantitative assessment of nocturnal neural respiratory drive in children with and without obstructive sleep apnoea using surface EMG. Experimental Physiology, 2019, 104, 755-764.	2.0	6
44	Assessing the quality of health care in the management of bronchiolitis in Australian children: a population-based sample survey. BMJ Quality and Safety, 2019, 28, 817-825.	3.7	3
45	Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children. BMC Pulmonary Medicine, 2019, 19, 71.	2.0	58
46	Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. Scientific Reports, 2019, 9, 18593.	3.3	84
47	Research priorities for childhood chronic conditions: a workshop report. Archives of Disease in Childhood, 2019, 104, 237-245.	1.9	16
48	Clinical indicators for common paediatric conditions: Processes, provenance and products of the CareTrack Kids study. PLoS ONE, 2019, 14, e0209637.	2.5	16
49	The contribution of viruses and bacteria to community-acquired pneumonia in vaccinated children: a case – control study. Thorax, 2019, 74, 261-269.	5.6	49
50	Association of Age at First Severe Respiratory Syncytial Virus Disease With Subsequent Risk of Severe Asthma: A Population-Based Cohort Study. Journal of Infectious Diseases, 2019, 220, 550-556.	4.0	19
51	Antibiotics for prolonged wet cough in children. Journal of Paediatrics and Child Health, 2019, 55, 110-113.	0.8	2
52	Research priority setting in childhood chronic disease: a systematic review. Archives of Disease in Childhood, 2018, 103, 942-951.	1.9	41
53	Helping refugee children thrive: what we know and where to next. Archives of Disease in Childhood, 2018, 103, 529-532.	1.9	5
54	Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: a case–control study protocol. BMJ Open, 2018, 8, e020646.	1.9	20

#	Article	IF	CITATIONS
55	Quality of Health Care for Children in Australia, 2012-2013. JAMA - Journal of the American Medical Association, 2018, 319, 1113.	7.4	77
56	Protective factors for social-emotional well-being of refugee children in the first three years of settlement in Australia. Archives of Disease in Childhood, 2018, 103, 261-268.	1.9	24
57	Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10 years old. Journal of Cystic Fibrosis, 2018, 17, 109-113.	0.7	16
58	Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine. Frontiers in Pharmacology, 2018, 9, 1429.	3.5	64
59	The School Experiences of Siblings of Children With Chronic Illness: Australian Parents' Perceptions. Educational and Developmental Psychologist, 2018, 35, 36-50.	0.7	4
60	Attentional Bias in Children with Asthma with and without Anxiety Disorders. Journal of Abnormal Child Psychology, 2017, 45, 1635-1646.	3.5	11
61	A Case Series Evaluation of a Pilot Group Cognitive Behavioural Treatment for Children With Asthma and Anxiety. Behaviour Change, 2017, 34, 35-47.	1.3	6
62	Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. Journal of Cystic Fibrosis, 2017, 16, 631-636.	0.7	43
63	Validation of a quantitative method to measure neural respiratory drive in children during sleep. Respiratory Physiology and Neurobiology, 2017, 239, 75-80.	1.6	3
64	Association of rhinovirus with exacerbations in young children affected by cystic fibrosis: Preliminary data. Journal of Medical Virology, 2017, 89, 1494-1497.	5.0	10
65	Parent-child interactions in children with asthma and anxiety. Behaviour Research and Therapy, 2017, 97, 242-251.	3.1	16
66	Rare disease registries: a call to action. Internal Medicine Journal, 2017, 47, 1075-1079.	0.8	33
67	Increased doses of inhaled corticosteroids during home management of asthma flareâ€ups do not reduce the need for systemic steroids. Journal of Paediatrics and Child Health, 2017, 53, 915-917.	0.8	1
68	Anxiety in youth with asthma: A meta-analysis. Pediatric Pulmonology, 2017, 52, 1121-1129.	2.0	122
69	Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high-risk Australian children: a whole-of-population-based cohort study. BMJ Open, 2017, 7, e017936.	1.9	19
70	Threat interpretation and parental influences for children with asthma and anxiety. Behaviour Research and Therapy, 2017, 89, 14-23.	3.1	20
71	Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade's experience. Orphanet Journal of Rare Diseases, 2017, 12, 133.	2.7	35
72	Respiratory syncytial virus is present in the neonatal intensive care unit. Journal of Medical Virology, 2016, 88, 196-201.	5.0	19

#	Article	IF	CITATIONS
73	High burden of RSV hospitalization in very young children: a data linkage study. Epidemiology and Infection, 2016, 144, 1612-1621.	2.1	52
74	Is there a role for stool metabolomics in cystic fibrosis?. Pediatrics International, 2016, 58, 808-811.	0.5	11
75	Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Internal Medicine Journal, 2016, 46, 1054-1062.	0.8	68
76	Persistent growth effects of inhaled corticosteroids. Journal of Paediatrics and Child Health, 2016, 52, 964-966.	0.8	3
77	Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Scientific Reports, 2016, 6, 24857.	3.3	85
78	Risk factors associated with RSV hospitalisation in the first 2â€years of life, among different subgroups of children in NSW: a whole-of-population-based cohort study. BMJ Open, 2016, 6, e011398.	1.9	23
79	Diagnosing cystic fibrosis-related diabetes: current methods and challenges. Expert Review of Respiratory Medicine, 2016, 10, 799-811.	2.5	18
80	A population study of respiratory rehospitalisation in very preterm infants in the first 3 years of life. Journal of Paediatrics and Child Health, 2016, 52, 715-721.	0.8	26
81	Resolution of Intestinal Histopathology Changes in Cystic Fibrosis after Treatment with Ivacaftor. Annals of the American Thoracic Society, 2016, 13, 297-298.	3.2	15
82	Diagnostic accuracy and distress associated with oropharyngeal suction in cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 473-478.	0.7	15
83	Absence of back to school peaks in human rhinovirus detections and respiratory symptoms in a cohort of children with asthma. Journal of Medical Virology, 2016, 88, 578-587.	5.0	11
84	Intestinal Inflammation and Impact on Growth in Children With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 521-526.	1.8	87
85	Use of the lung flute for sputum induction in children with cystic fibrosis: A pilot study. Pediatric Pulmonology, 2015, 50, 340-343.	2.0	6
86	Advances in the detection and management of cystic fibrosis related diabetes. Current Opinion in Pediatrics, 2015, 27, 525-533.	2.0	25
87	CareTrack Kids-part 1. Assessing the appropriateness of healthcare delivered to Australian children: study protocol for clinical indicator development. BMJ Open, 2015, 5, e007748-e007748.	1.9	30
88	CareTrack Kids–part 2. Assessing the appropriateness of the healthcare delivered to Australian children: study protocol for a retrospective medical record review. BMJ Open, 2015, 5, e007749-e007749.	1.9	27
89	CareTrack Kids–part 3. Adverse events in children's healthcare in Australia: study protocol for a retrospective medical record review. BMJ Open, 2015, 5, e007750-e007750.	1.9	9
90	Presentation of primary ciliary dyskinesia in children: 30 years' experience. Journal of Paediatrics and Child Health, 2015, 51, 722-726.	0.8	48

#	Article	IF	CITATIONS
91	A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation. European Respiratory Journal, 2015, 45, 541-544.	6.7	11
92	Childhood interstitial lung disease: A systematic review. Pediatric Pulmonology, 2015, 50, 1383-1392.	2.0	58
93	Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?. Digestive Diseases and Sciences, 2015, 60, 2946-2952.	2.3	23
94	Elevated fecal <scp>M</scp> 2â€pyruvate kinase in children with cystic fibrosis: A clue to the increased risk of intestinal malignancy in adulthood?. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 866-871.	2.8	26
95	Rhinoviruses significantly affect day-to-day respiratory symptoms of children with asthma. Journal of Allergy and Clinical Immunology, 2015, 135, 663-669.e12.	2.9	27
96	Markers of pancreatic function in the breath. Journal of Breath Research, 2014, 8, 046009.	3.0	3
97	Fat-soluble vitamin deficiency in children and adolescents with cystic fibrosis. Journal of Clinical Pathology, 2014, 67, 605-608.	2.0	36
98	Not yet time to change to intermittent inhaled corticosteroids for persistent asthma in children. Journal of Paediatrics and Child Health, 2014, 50, 588-590.	0.8	0
99	Markers of Inflammation in the Breath in Paediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 505-510.	1.8	8
100	Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective. International Journal of Pediatrics (United Kingdom), 2014, 2014, 1-13.	0.8	76
101	Cannabis smoking and respiratory health: Consideration of the literature. Respirology, 2014, 19, 655-662.	2.3	70
102	Annual Review Clinic improves care in children with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 186-189.	0.7	6
103	<scp>P</scp> rimary ciliary dyskinesia: Overlooked and undertreated in children. Journal of Paediatrics and Child Health, 2014, 50, 952-958.	0.8	15
104	Childhood interstitial lung disease due to surfactant protein C deficiency: frequent use and costs of hospital services for a single case in Australia. Orphanet Journal of Rare Diseases, 2014, 9, 36.	2.7	9
105	Caregiver Coping, Mental Health and Child Problem Behaviours in Cystic Fibrosis: A Cross-Sectional Study. International Journal of Behavioral Medicine, 2014, 21, 211-220.	1.7	21
106	Single high-dose oral vitamin D3 (stoss) therapy — A solution to vitamin D deficiency in children with cystic fibrosis?. Journal of Cystic Fibrosis, 2013, 12, 177-182.	0.7	43
107	The association between maternal country of birth and neonatal intensive care unit outcomes. Early Human Development, 2013, 89, 607-614.	1.8	8
108	Exhaled breath condensate in pediatric asthma: Promising new advance or pouring cold water on a lot of hot air? A systematic review. Pediatric Pulmonology, 2013, 48, 419-442.	2.0	52

#	Article	IF	CITATIONS
109	Increased paediatric hospitalizations for empyema in Australia after introduction of the 7-valent pneumococcal conjugate vaccine. Bulletin of the World Health Organization, 2013, 91, 167-173.	3.3	36
110	Shared <i>Pseudomonas aeruginosa</i> genotypes are common in Australian cystic fibrosis centres. European Respiratory Journal, 2013, 41, 1091-1100.	6.7	59
111	Update of Faecal Markers of Inflammation in Children with Cystic Fibrosis. Mediators of Inflammation, 2012, 2012, 1-6.	3.0	46
112	The natural history and predictors of persistent problem behaviours in cystic fibrosis: a multicentre, prospective study. Archives of Disease in Childhood, 2012, 97, 625-631.	1.9	21
113	Once daily insulin detemir in cystic fibrosis with insulin deficiency. Archives of Disease in Childhood, 2012, 97, 464-467.	1.9	49
114	Noninvasive Monitoring of Glucose Levels: Is Exhaled Breath the Answer?. Journal of Diabetes Science and Technology, 2012, 6, 659-664.	2.2	15
115	Comparison of the US and Australian Cystic Fibrosis Registries: The Impact of Newborn Screening. Pediatrics, 2012, 129, e348-e355.	2.1	46
116	Early Cystic Fibrosis Lung Disease Detected by Bronchoalveolar Lavage and Lung Clearance Index. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 862-873.	5.6	125
117	Cost Considerations of Therapeutic Options for Children with Asthma. Paediatric Drugs, 2012, 14, 211-220.	3.1	2
118	Acid and nonâ€acid reflux during physiotherapy in young children with cystic fibrosis. Pediatric Pulmonology, 2012, 47, 119-124.	2.0	26
119	Childhood wheeze while taking propranolol for treatment of infantile hemangiomas. Pediatric Pulmonology, 2012, 47, 713-715.	2.0	5
120	Pleural fluid nucleic acid testing enhances pneumococcal surveillance in children. Respirology, 2012, 17, 114-119.	2.3	18
121	Expression of PPARÎ ³ and Paraoxonase 2 Correlated with Pseudomonas aeruginosa Infection in Cystic Fibrosis. PLoS ONE, 2012, 7, e42241.	2.5	26
122	Bacterial Causes of Empyema in Children, Australia, 2007–2009. Emerging Infectious Diseases, 2011, 17, 1839-1845.	4.3	46
123	A bedside assay to detect <i>streptococcus pneumoniae</i> in children with empyema. Pediatric Pulmonology, 2011, 46, 179-183.	2.0	14
124	Cystic Fibrosis Related Diabetes (CFRD)—The End Stage of Progressive Insulin Deficiency. Pediatric Pulmonology, 2011, 46, 747-760.	2.0	46
125	The Role of Azithromycin in Patients with Cystic Fibrosis. Paediatric Respiratory Reviews, 2010, 11, 108-114.	1.8	39
126	Chemosensory function and food preferences of children with cystic fibrosis. Pediatric Pulmonology, 2010, 45, 807-815.	2.0	16

#	Article	IF	CITATIONS
127	Call for a national plan for rare diseases. Journal of Paediatrics and Child Health, 2010, 46, 2-4.	0.8	46
128	Early Glucose Abnormalities in Cystic Fibrosis Are Preceded by Poor Weight Gain. Diabetes Care, 2010, 33, 221-226.	8.6	145
129	Body composition assessed by the 4-component model and association with lung function in 6–12-y-old children with cystic fibrosis. American Journal of Clinical Nutrition, 2010, 92, 1332-1343.	4.7	23
130	Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function. Thorax, 2009, 64, 246-251.	5.6	69
131	Problem behaviours and parenting in preschool children with cystic fibrosis. Archives of Disease in Childhood, 2009, 94, 341-347.	1.9	42
132	Pneumococcal empyema and haemolytic uraemic syndrome in children: experience from a UK tertiary respiratory centre. Archives of Disease in Childhood, 2009, 94, 645-646.	1.9	8
133	Strategies for reducing the burden of respiratory syncytial virus in high-risk infants. Pediatric Health, 2009, 3, 391-406.	0.3	1
134	A REVIEW OF POSTNATAL MANAGEMENT OF CONGENITAL PULMONARY AIRWAY MALFORMATIONS. Fetal and Maternal Medicine Review, 2009, 20, 179-204.	0.3	3
135	Pulmonary cysts in early childhood and the risk of malignancy. Pediatric Pulmonology, 2009, 44, 14-30.	2.0	257
136	Bronchiectasis secondary to primary immunodeficiency in children: Longitudinal changes in structure and function. Pediatric Pulmonology, 2009, 44, 669-675.	2.0	62
137	Assessment of the burden of paediatric empyema in Australia. Journal of Paediatrics and Child Health, 2009, 45, 431-436.	0.8	38
138	Lymphocytic Leiomyositis and Myenteric Ganglionitis Are Intrinsic Features of Cystic Fibrosis: Studies in Distal Intestinal Obstruction Syndrome and Meconium Ileus. Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 42-51.	1.8	26
139	Ventilation induced pneumothorax following resolved empyema. Pediatric Pulmonology, 2008, 43, 99-101.	2.0	1
140	Establishment of a webâ€based registry for rare (orphan) pediatric lung diseases in the United Kingdom: The BPOLD registry. Pediatric Pulmonology, 2008, 43, 451-456.	2.0	30
141	Atypical invasive aspergillosis in a neutropenic child. Pediatric Pulmonology, 2008, 43, 717-720.	2.0	0
142	Undercarboxylated osteocalcin and bone mass in 8–12Âyear old children with cystic fibrosis. Journal of Cystic Fibrosis, 2008, 7, 307-312.	0.7	36
143	Role of routine computed tomography in paediatric pleural empyema. Thorax, 2008, 63, 897-902.	5.6	71
144	A Receptor-targeted Nanocomplex Vector System Optimized for Respiratory Gene Transfer. Molecular Therapy, 2008, 16, 907-915.	8.2	59

#	Article	IF	CITATIONS
145	Asthma and gastroesophageal reflux in children: cause or effect? Current and novel approaches. Pediatric Health, 2008, 2, 333-339.	0.3	1
146	Infants with chronic neonatal lung disease: recommendations for the use of home oxygen therapy. Medical Journal of Australia, 2008, 189, 578-582.	1.7	52
147	Consent in paediatric research: an evaluation of the guidance provided in the 2007 NHMRC National statement on ethical conduct in human research. Medical Journal of Australia, 2008, 189, 347-348.	1.7	4
148	Paediatric prescribing of asthma drugs in the UK: are we sticking to the guideline?. Archives of Disease in Childhood, 2007, 92, 847-849.	1.9	39
149	The role of communication in paediatric drug safety. Archives of Disease in Childhood, 2007, 92, 440-445.	1.9	33
150	Treatment approaches for empyema in children. Paediatric Respiratory Reviews, 2007, 8, 164-170.	1.8	28
151	Immunomodulatory Effects of Macrolide Antibiotics in Respiratory Disease. Paediatric Drugs, 2007, 9, 107-118.	3.1	27
152	Vitamin K prescribing patterns and bone health surveillance in UK children with cystic fibrosis. Journal of Human Nutrition and Dietetics, 2007, 20, 605-610.	2.5	11
153	Comparison of Urokinase and Video-assisted Thoracoscopic Surgery for Treatment of Childhood Empyema. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 221-227.	5.6	303
154	Modifier effect of the Toll-like receptor 4 D299G polymorphism in children with cystic fibrosis. Archivum Immunologiae Et Therapiae Experimentalis, 2006, 54, 271-276.	2.3	8
155	Gene therapy for children with cystic fibrosiswho has the right to choose?. Journal of Medical Ethics, 2006, 32, 361-364.	1.8	23
156	Safety and feasibility of exhaled breath condensate collection in ventilated infants and children. European Respiratory Journal, 2006, 28, 479-485.	6.7	18
157	Evaluation of Arm Anthropometry for Assessing Pediatric Body Composition: Evidence from Healthy and Sick Children. Pediatric Research, 2006, 59, 860-865.	2.3	97
158	Macrolides in cystic fibrosis. , 2005, , 167-191.		6
159	Management of empyema in children. Pediatric Pulmonology, 2005, 40, 148-156.	2.0	86
160	Orphan lung diseases in childhood: still unadopted?. Thorax, 2005, 60, 892-894.	5.6	6
161	Potential Difference Measurements in the Lower Airway of Children with and without Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1015-1019.	5.6	34
162	Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?. European Respiratory Journal, 2005, 26, 8-14.	6.7	179

#	Article	IF	CITATIONS
163	Transbronchial biopsies provide longitudinal evidence for epithelial chimerism in children following sex mismatched lung transplantation. Thorax, 2005, 60, 60-62.	5.6	60
164	257 Malondialdehyde in Plasma and Exhaled Breath Condensate Collected from Ventilated Infants. Pediatric Research, 2005, 58, 398-398.	2.3	1
165	Assessment of hypoxia in children with cystic fibrosis. Archives of Disease in Childhood, 2005, 90, 1138-1143.	1.9	43
166	Clinical improvement in cystic fibrosis following anti-tumourous chemotherapy. Archives of Disease in Childhood, 2004, 89, 1179-1180.	1.9	5
167	Chronic pneumonitis of infancy: high-resolution CT findings. Pediatric Radiology, 2004, 34, 86-88.	2.0	15
168	Comparison of active cycle of breathing and high-frequency oscillation jacket in children with cystic fibrosis. Pediatric Pulmonology, 2004, 37, 71-75.	2.0	41
169	Primary thoracoscopic treatment of empyema in children. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 79-84.	0.8	86
170	An alternative to lung transplantation. Pediatric Pulmonology, 2003, 36, 357-358.	2.0	2
171	Exhaled nitric oxide increases following admission for intravenous antibiotics in children with cystic fibrosis. Journal of Cystic Fibrosis, 2003, 2, 143-147.	0.7	18
172	Disabling cough: habit disorder or tic syndrome?. Lancet, The, 2003, 361, 1991-1992.	13.7	5
173	Newer therapies for cystic fibrosis. Current Paediatrics, 2003, 13, 259-263.	0.2	3
174	A baby with cough and poor feeding. European Respiratory Journal, 2003, 22, 182-185.	6.7	10
175	Thoracic empyema. Archives of Disease in Childhood, 2003, 88, 839-841.	1.9	31
176	High incidence of cystic fibrosis in children born in Italy to Albanian immigrants. Thorax, 2003, 58, 93-93.	5.6	7
177	Are annual blood tests in preschool cystic fibrosis patients worthwhile?. Archives of Disease in Childhood, 2002, 87, 518-520.	1.9	5
178	Treatment of Severe Small Airways Disease in Children with Cystic Fibrosis. Paediatric Drugs, 2002, 4, 381-389.	3.1	12
179	Macrolides in the respiratory tract in cystic fibrosis. Journal of the Royal Society of Medicine, 2002, 95 Suppl 41, 27-31.	2.0	2
180	Genetic contributions to rare childhood lung diseases. Paediatric Respiratory Reviews, 2001, 2, 268-275.	1.8	1

#	Article	IF	CITATIONS
181	Routine ventilation scans in children with cystic fibrosis: diagnostic usefulness and prognostic value. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1313-1318.	2.1	14
182	Antiâ€inflammatory effects of macrolides in lung disease. Pediatric Pulmonology, 2001, 31, 464-473.	2.0	194
183	Cationic lipid-mediated gene transfer to the growing murine and human airway. Gene Therapy, 2000, 7, 273-278.	4.5	8
184	The <i>In Vivo</i> Effects of Milrinone on the Airways of Cystic Fibrosis Mice and Human Subjects. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 129-134.	2.9	54
185	If you can't stand the rash, get out of the kitchen: An unusual adverse reaction to ciprofloxacin. , 1999, 28, 449-450.		12
186	Pulmonary disease severity in men with ΔF508 cystic fibrosis and residual chloride secretion. Lancet, The, 1999, 353, 984-985.	13.7	33
187	Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet, The, 1999, 353, 947-954.	13.7	425
188	Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet, The, 1998, 351, 420.	13.7	262
189	Probiotics for people with cystic fibrosis. The Cochrane Library, 0, , .	2.8	3
190	Detection and Management of Early Glucose Abnormalities in Cystic Fibrosis. , 0, , .		1

Detection and Management of Early Glucose Abnormalities in Cystic Fibrosis. , 0, , . 190